Astrazeneca Pharma India Ltd (ASTRAZEN) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap

Astrazeneca Pharma I Share Price

9,230.50 41.60 0.45%
as on 05-Dec'25 15:45

Astrazeneca Pharma India Ltd (ASTRAZEN) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Astrazeneca Pharma I

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Astrazeneca Pharma India stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
115.35
Market Cap:
22,972.3 Cr.
52-wk low:
6,301
52-wk high:
10,653.1

Is Astrazeneca Pharma India Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Astrazeneca Pharma I: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 3.8%18.7%18.7%26.5%34.6%31.2%17.4%24.5%33.9%21.3%-
Value Creation
Index
-0.70.30.30.91.61.30.30.81.50.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5645445717288328148061,0031,2961,7162,006
Sales YoY Gr.--3.6%5%27.6%14.2%-2.2%-1%24.5%29.2%32.5%-
Adj EPS 2.25.910.521.628.936.923.950.260.173.479.7
YoY Gr.-171.6%76.5%106.5%34.1%27.4%-35.2%110.1%19.8%22.1%-
BVPS (₹) 62.488.597.9119.5145.1181.8203.8234.5283.5305.3319.6
Adj Net
Profit
5.514.826.15472.392.259.7126150184199
Cash Flow from Ops. 5738.18.85587.410510158.327.965.4-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.2%15.6%28.7%32.5%
Adj EPS 47.8%20.5%45.4%22.1%
BVPS19.3%16%14.4%7.7%
Share Price 23.7% 15.4% 40.9% 39.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
3.67.811.119.721.722.512.322.823.124.825.5
Op. Profit
Mgn %
36.98.29.814.616.710.716.514.314.815.9
Net Profit
Mgn %
12.74.67.48.711.37.412.511.610.79.9
Debt to
Equity
00000000000
Working Cap
Days
167185216176167193200185179206121
Cash Conv.
Cycle
171112-0-2-164235057

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Astrazeneca Pharma India Ltd.

Standalone Consolidated
TTM EPS (₹) 79.7 -
TTM Sales (₹ Cr.) 2,006 -
BVPS (₹.) 319.6 -
Reserves (₹ Cr.) 794 -
P/BV 28.75 -
PE 115.35 -
From the Market
52 Week Low / High (₹) 6301.00 / 10653.05
All Time Low / High (₹) 9.00 / 10653.05
Market Cap (₹ Cr.) 22,972
Equity (₹ Cr.) 5
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Astrazeneca Pharma I:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Astrazeneca Pharma I - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Astrazeneca Pharma I

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales5645445717288328148061,0031,2961,716
Operating Expenses 5475075256577116787198381,1111,462
Manufacturing Costs33445958495765829454
Material Costs195171178227300287305355590958
Employee Cost 169162150197217220230259241257
Other Costs 150129137175146115119142185193
Operating Profit 1637467112113586165184254
Operating Profit Margin (%) 2.9%6.8%8.1%9.8%14.5%16.7%10.7%16.5%14.2%14.8%
Other Income 7141216131315263541
Interest 0000111111
Depreciation 17161515192017161540
Exceptional Items 0000000-4016-97
Profit Before Tax 636447311412783134220156
Tax 1151818423421355841
Profit After Tax 520265472936299162116
PAT Margin (%) 0.9%3.7%4.5%7.5%8.7%11.5%7.6%9.9%12.5%6.7%
Adjusted EPS (₹)2.18.010.421.828.937.324.639.764.646.3
Dividend Payout Ratio (%)0%0%0%0%3%5%41%40%37%69%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 156221245299363455509586709763
Share Capital 5555555555
Reserves 151216240294358450504581704758
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables9588127168210178190228197456
Others Liabilities 178205203124203241277328372618
Total Liabilities 4295145755917768749771,1421,2771,838

Fixed Assets

Gross Block204103106120133160169179187218
Accumulated Depreciation106163045617994110120153
Net Fixed Assets 97877575728174696764
CWIP 65472442100
Investments 0000000000
Inventories7758113118165160140190228549
Trade Receivables83435580838586108153185
Cash Equivalents flag 77116126173253352448500506537
Others Assets 89206203138179192226274323503
Total Assets 4295145755917768749771,1421,2771,838

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 573895587105101582865
PBT 636447311412783134220156
Adjustment 121538101410-5-776
Changes in Working Capital 42-0-3410-3-433-30-128-103
Tax Paid -3-12-4-35-34-33-25-41-56-64
Cash Flow From Investing Activity -40-94-1711735182231
Capex -9-5-6-18-14-5-6-5-10-1
Net Investments 00-1112-1691690000
Others 5681112911233232
Cash Flow From Financing Activity -1000-6-9-9-24-44-66
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -0000-1-1-1-1-1-1
Dividend Paid 0000-3-5-5-20-40-60
Others -0000-3-3-4-4-4-4
Net Cash Flow 5338-159-902699652531

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3.4310.6311.1220.0321.8322.8312.7818.1324.9515.73
ROCE (%)3.7618.7418.6526.5334.6131.2417.3624.4933.9421.29
Asset Turnover Ratio1.361.161.051.251.220.990.870.951.081.11
PAT to CFO Conversion(x)11.41.90.351.021.211.131.630.590.170.56
Working Capital Days
Receivable Days40423134363839353736
Inventory Days52455558627368605982
Payable Days193194220238230247220215131124

Astrazeneca Pharma India Ltd Stock News

Astrazeneca Pharma India Ltd FAQs

The current trading price of Astrazeneca Pharma I on 05-Dec-2025 15:45 is ₹9,230.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Astrazeneca Pharma I stood at ₹22,972.3.
The latest P/E ratio of Astrazeneca Pharma I as of 04-Dec-2025 is 115.3.
The latest P/B ratio of Astrazeneca Pharma I as of 04-Dec-2025 is 28.75.
The 52-week high of Astrazeneca Pharma I is ₹10,653.1 and the 52-week low is ₹6,301.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astrazeneca Pharma I is ₹2,006 ( Cr.) .

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×